GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Science Sun Pharmaceutical Co Ltd (SZSE:300485) » Definitions » Gross-Profit-to-Asset %

Beijing Science Sun Pharmaceutical Co (SZSE:300485) Gross-Profit-to-Asset % : 8.23% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Beijing Science Sun Pharmaceutical Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Beijing Science Sun Pharmaceutical Co's annualized Gross Profit for the quarter that ended in Mar. 2024 was ¥289.5 Mil. Beijing Science Sun Pharmaceutical Co's average Total Assets over the quarter that ended in Mar. 2024 was ¥3,516.2 Mil. Therefore, Beijing Science Sun Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 8.23%.


Beijing Science Sun Pharmaceutical Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Beijing Science Sun Pharmaceutical Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Science Sun Pharmaceutical Co Gross-Profit-to-Asset % Chart

Beijing Science Sun Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.46 31.64 27.18 16.15 9.33

Beijing Science Sun Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.64 11.03 9.14 5.95 8.23

Competitive Comparison of Beijing Science Sun Pharmaceutical Co's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Science Sun Pharmaceutical Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Science Sun Pharmaceutical Co's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beijing Science Sun Pharmaceutical Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Beijing Science Sun Pharmaceutical Co's Gross-Profit-to-Asset % falls into.



Beijing Science Sun Pharmaceutical Co Gross-Profit-to-Asset % Calculation

Beijing Science Sun Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=335.63/( (3569.083+3622.202)/ 2 )
=335.63/3595.6425
=9.33 %

Beijing Science Sun Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=289.496/( (3622.202+3410.25)/ 2 )
=289.496/3516.226
=8.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Beijing Science Sun Pharmaceutical Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Beijing Science Sun Pharmaceutical Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Science Sun Pharmaceutical Co (SZSE:300485) Business Description

Traded in Other Exchanges
N/A
Address
No. 8, Xingsheng Street, Yizhuang Economic and Technological Development Zone, Beijing, CHN, 100176
Beijing Science Sun Pharmaceutical Co Ltd is engaged in the research and development, production and sales of biological drugs. The company products can be divided into cardiovascular series, immune regulation series, nervous system series, and other natural or biotech pharmaceuticals. Its products include Injection Tiopronin, Cybex, Xel, Lichinga, Plasmin Injection and Race liter.
Executives
Ma Li Directors, executives
Kong Shuang Quan Executives
Li Jian Hua Director
Ma Biao Directors, executives
Li Zhi Bing Supervisors
Zhang Fan Executives

Beijing Science Sun Pharmaceutical Co (SZSE:300485) Headlines

No Headlines